Skip to main content

ARCH Venture Partners — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

236
Companies
$19.0B
Total invested
$113.2M
Avg. check
22
Industries
Biotechnology 19Medical 12Health Care 10Therapeutics 10Life Science 8Biopharma 6+16 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 236
Rapport Therapeutics
September 2025

Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.

Biotechnology · Boston$250.0M Post-IPO Equity
Altos Labs
September 2021

Altos Labs focuses on cellular rejuvenation programming to restore cell health and resilience, to reverse disease to transform medicine.

Biopharma · San Francisco$3.0B Series A
EGenesis
September 2024

EGenesis is a gene editing and genome engineering company developing human-compatible engineered organs to treat diseases.

Biopharma · Cambridge$191.0M Series D
ArsenalBio
September 2024

ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors.

Biotechnology · South San Francisco$325.0M Series C
Excision BioTherapeutics
September 2022

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Biotechnology · Philadelphia$6.8M Grant
Volastra Therapeutics
September 2025

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Biotechnology · New York$30.1M Series A
Mindstrong Health
September 2022

Mindstrong is a virtual mental health platform.

Health Care · Menlo Park$250K Grant
AgBiome
September 2021

AgBiome discovers and develops innovative biological and trait products for crop protection.

Agriculture · Raleigh$116.0M Series D
Codiak Biosciences
September 2022

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Biotechnology · San Francisco$20.0M Post-IPO Equity
Happy Health
August 2022

Happy Health is a mission-driven technology company

Health Care · Austin$60.0M Series A
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Lyell Immunopharma
July 2025

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Biotechnology · South San Francisco$100.0M Post-IPO Equity
Ultivue
July 2024

Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.

Biopharma · Cambridge$3.3M Venture - Series Unknown
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
Dispatch Bio
July 2025

Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.

Biotechnology · Philadelphia$216.0M Series A
Pretzel Therapeutics
July 2025

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Biotechnology · WalthamVenture - Series Unknown
Gossamer Bio
July 2023

Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.

Biotechnology · San Diego$212.0M Post-IPO Equity
City Therapeutics
June 2026

City Therapeutics is a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines for a range of diseases.

Biopharma · Cambridge$99.5M Series B
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Bitterroot Bio
June 2023

Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.

Biotechnology · Palo Alto$145.0M Series A
Advanced Medicine Partners
June 2024

Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells.

Biotechnology · Lake Forest$32.0M Series A
Trase
June 2026

Trase Systems is an AI firm that provides safety and security to organisation to run there administrative workflows and processes.

Artificial Intelligence (AI) · Mclean$107.0M Seed
Ollin Biosciences
June 2026

Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.

Biopharma · Austin$330.0M Series B
Parabilis Medicines
June 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$75.0M Post-IPO Equity

Where ARCH Venture Partners invests

Biotechnology19
Medical12
Health Care10
Therapeutics10
Life Science8
Biopharma6

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?

ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?

ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Life Science. The firm invests across 22 different industry categories.

What is ARCH Venture Partners's largest investment?

Among tracked funding rounds, Altos Labs received $3.0B in a Series A round. ARCH Venture Partners's total known invested capital is $19.0B.

What is the average investment size for ARCH Venture Partners?

ARCH Venture Partners's average investment size is $113.2M across its portfolio of 236 companies.

What are ARCH Venture Partners's most recent investments?

Recent ARCH Venture Partners portfolio additions include Rapport Therapeutics, Altos Labs, EGenesis, ArsenalBio, Excision BioTherapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 236 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →